{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2003"],"condition":["Colorectal Cancer (CRC)","Metastatic Colorectal Cancer resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin","Colorectal Neoplasms"],"disease":["Colorectal Cancer (crc)","Metastatic Colorectal Cancer Resistant To Or Unsuitable For Treatment With 5-fluorouracil And Irinotecan And/or Oxaliplatin","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2016943"],"location":["Netherlands","France","Germany"],"study_start_month":["3"],"keyword":["indisulam","Xeloda 150 mg film-coated tablets","N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide","Xeloda 500 mg film-coated tablets"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer","description":"Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.","dates":{"creation":"2003-03-15"},"accession":"2016943","cross_references":{"ClinicalTrials___gov":["NCT00165854"],"EU Clinical Trials Register":["2004-002597-33"]}}